Shi et al. [31] found that advanced hepatocellular carcinoma (HCC) overexpressed SPHK-2 and developed resistance to the anticancer drug regorafenib and that silencing SPHK-2 expression restored the sensitivity of HCC to regorafenib. The gene discussed is SPHK2; the disease is hepatocellular carcinoma.